Expand PHGE Menu
PHGE MENU

PHGE Latest Press Releases

-- April 23, 2024 --

BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024) Globe Newswire 8:00 AM

-- April 18, 2024 --

BiomX Announces the Appointment of Susan Blum to its Board of Directors Globe Newswire 8:00 AM

-- April 4, 2024 --

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure Globe Newswire 7:49 AM

-- April 3, 2024 --

BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Globe Newswire 6:30 AM

-- March 27, 2024 --

BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024 Globe Newswire 6:30 AM

-- March 19, 2024 --

Telum Therapeutics appoints Dr. Subhendu Basu as CEO PRNewswire 5:00 AM

-- March 18, 2024 --

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing Globe Newswire 6:30 AM

-- March 7, 2024 --

Shareholder Alert: Ademi LLP investigates the transaction between BiomX Inc. and Adaptive Phage Therapeutics PRNewswire 3:45 AM

-- March 6, 2024 --

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing Globe Newswire 7:30 AM

-- January 4, 2024 --

BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis Globe Newswire 8:00 AM